...
首页> 外文期刊>Toxicological sciences: An official journal of the Society of Toxicology >Down selection of polymerized bovine hemoglobins for use as oxygen releasing therapeutics in a Guinea pig model
【24h】

Down selection of polymerized bovine hemoglobins for use as oxygen releasing therapeutics in a Guinea pig model

机译:向下选择聚合牛血红蛋白作为豚鼠模型中的氧气释放治疗剂

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Hemoglobin (Hb)-based oxygen carriers (HBOCs) are being developed as resuscitative fluids for use in multiple medical applications and in lieu of blood transfusion. However, cardiovascular, central nervous system, and renal adverse events have largely impeded progress. This has prompted a need to evaluate novel down selection approaches for HBOCs prior to in-depth preclinical and clinical safety testing. In the present study, polymerized bovine Hbs (PolybHbs) were prepared with increasing ratios of glutaraldehyde to bovine Hb (10:1, 20:1, 30:1, and 40:1). The optimal PolybHb candidate selection was based on a priori determined in vivo response to include a long circulating PolybHb with no measurable renal exposure, minimal cardiovascular response, limited oxidation to metHb in vitro, or in circulation and absence of acute end organ toxicity. Guinea pigs were dosed via a 50% blood for PolybHb exchange transfusion. Data suggested that the 30:1 preparation exhibited maximum circulatory exposure (AUC 0-∞) with the lowest level of oxidation (plasma metHb formation) and minimal ( 10%) blood pressure elevation. Additionally, the 30:1 preparation was absent renal iron deposition as well as abnormal glomerular/tubular histopathology or serum creatinine elevation. Clearance pathways predominantly followed those consistent with endogenous Hb clearance based pathways. Therefore, data confirmed the ability to select a single PolybHb from a small library of HBOCs based on a priori determined characteristics. Moreover, the approach to down selection described could be applied to enhance the early predictability of human safety for this class of biological therapeutics to optimize for specific indications.
机译:正在开发基于血红蛋白(Hb)的氧气载体(HBOC)作为复苏液,可用于多种医疗应用并代替输血。但是,心血管,中枢神经系统和肾脏不良事件严重阻碍了进展。因此,有必要在进行深入的临床前和临床安全性测试之前,对HBOC的新型选择方法进行评估。在本研究中,制备的聚合牛血红蛋白(PolybHbs)的戊二醛与牛血红蛋白的比例增加(10:1、20:1、30:1和40:1)。最佳的PolybHb候选药物选择基于事先确定的体内反应,包括长循环的PolybHb,没有可测量的肾脏暴露,最小的心血管反应,体外或在循环中对metHb的氧化有限,并且没有急性端器官毒性。豚鼠通过50%的血液进行PolybHb交换输血。数据表明30:1制剂表现出最大的循环暴露(AUC0-∞),氧化水平最低(血浆metHb形成),血压升高最小(<10%)。此外,该30:1制剂缺乏肾铁沉积以及异常的肾小球/肾小管组织病理学或血清肌酐升高。清除途径主要遵循与内源性基于Hb清除的途径一致的途径。因此,数据证实了根据先验确定的特征从小型HBOC库中选择单个PolybHb的能力。此外,所描述的向下选择的方法可以用于增强人类安全性对此类生物治疗剂的早期可预测性,以针对特定适应症进行优化。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号